Effect of Deutetrabenazine on QTcF Interval in the AIM-TD Study: a 12-Week, Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Objective: To evaluate the effect of deutetrabenazine (DTB) on QT interval prolongation in patients with tardive dyskinesia (TD) in the AIM-TD study. Background: TD is…Tardive syndromes induced by coadministration of tramadol and sertralin
Objective: To illustrate the possible association of tardive syndromes (TS) and coadministration of tramadol and sertraline in three patients. Background: TS is delayed onset of…Low Incidence of Extrapyramidal Symptoms in Subjects with Tardive Dyskinesia Receiving Long-Term Valbenazine (NBI-98854) Treatment
Objective: To assess the emergence of extrapyramidal symptoms (EPS) such as akathisia and parkinsonism in adults with a diagnosis of schizophrenia/schizoaffective disorder or mood disorder…Laryngeal Tardive Dyskinesia in a Patient treated with Haldol
Objective: To describe the case of woman with post stroke hemiballism treated chronically with Haldol who developed laryngeal tardive dystonia and to review the current…Drug-induced movement disorders: not a typical problem
Objective: To characterize patients with neuroleptic drug-induced movement disorders (DIMD) referred to a single academic center Movement Disorders clinic, their causative medications and the indications…Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study
Objective: To evaluate the long-term safety/tolerability of deutetrabenazine (DTB) in patients with tardive dyskinesia (TD). Week 54 open-label results are reported in this interim analysis.…Effect of Deutetrabenazine on Quality of Life in Patients With Tardive Dyskinesia in AIM-TD, a 12-Week Double-Blind, Placebo-Controlled Study
Objective: To assess the effect of deutetrabenazine (DTB) on quality of life (QoL) of patients with tardive dyskinesia (TD) as measured by the modified Craniocervical…Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies
Objective: To evaluate the efficacy of deutetrabenazine (DTB), as measured by the Clinical Global Impression of Change (CGIC), in patients with tardive dyskinesia (TD) from…An MCID for AIMS Dyskinesia Total Score Change in Subjects with Tardive Dyskinesia
Objective: To establish a minimal clinically important difference (MCID) for Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score change using data from randomized, double-blind, placebo…Risk of movement disorders with antipsychotic drugs in patients with schizophrenia or depressive disorders
Objective: To compare the risk of movement disorders with antipsychotic drugs (APDs) in patients suffering from Schizophrenia or Depressive Disorders. Background: APDs are well-known causes…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- Next Page »